Quince Therapeutics, Inc. (QNCX) - Total Assets
Based on the latest financial reports, Quince Therapeutics, Inc. (QNCX) holds total assets worth $109.90 Million USD as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See Quince Therapeutics, Inc. (QNCX) shareholders funds for net asset value and shareholders' equity analysis.
Quince Therapeutics, Inc. - Total Assets Trend (2017–2024)
This chart illustrates how Quince Therapeutics, Inc.'s total assets have evolved over time, based on quarterly financial data.
Quince Therapeutics, Inc. - Asset Composition Analysis
Current Asset Composition (December 2024)
Quince Therapeutics, Inc.'s total assets of $109.90 Million consist of 38.5% current assets and 61.5% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 5.4% |
| Accounts Receivable | $882.00K | 0.8% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $60.05 Million | 52.5% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2017–2024)
This chart illustrates how Quince Therapeutics, Inc.'s asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Quince Therapeutics, Inc. (QNCX) total market value.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Quince Therapeutics, Inc.'s current assets represent 38.5% of total assets in 2024, a decrease from 97.7% in 2017.
- Cash Position: Cash and equivalents constituted 5.4% of total assets in 2024, down from 95.1% in 2017.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 52.0% of total assets, an increase from 0.0% in 2017.
- Asset Diversification: The largest asset category is intangible assets at 52.5% of total assets.
Quince Therapeutics, Inc. Competitors by Total Assets
Key competitors of Quince Therapeutics, Inc. based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Fortress Biotech Inc
NASDAQ:FBIO
|
USA | $185.55 Million |
|
Summit Therapeutics PLC
NASDAQ:SMMT
|
USA | $261.73 Million |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.93 Billion |
|
Apellis Pharmaceuticals Inc
NASDAQ:APLS
|
USA | $1.08 Billion |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161
|
China | CN¥16.55 Billion |
|
BrightGene Bio Medical Technology C
SHG:688166
|
China | CN¥5.38 Billion |
|
BioArctic AB (publ)
ST:BIOA-B
|
Sweden | Skr2.60 Billion |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
Quince Therapeutics, Inc. - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.12 | 9.53 | 8.11 |
| Quick Ratio | 1.12 | 9.53 | 8.11 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $3.16 Million | $46.29 Million | $120.87 Million |
Quince Therapeutics, Inc. - Advanced Valuation Insights
This section examines the relationship between Quince Therapeutics, Inc.'s asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 10.51 |
| Latest Market Cap to Assets Ratio | 0.10 |
| Asset Growth Rate (YoY) | -36.5% |
| Total Assets | $114.48 Million |
| Market Capitalization | $11.14 Million USD |
Valuation Analysis
Below Book Valuation: The market values Quince Therapeutics, Inc.'s assets below their book value (0.10x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Quince Therapeutics, Inc.'s assets decreased by 36.5% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Quince Therapeutics, Inc. (2017–2024)
The table below shows the annual total assets of Quince Therapeutics, Inc. from 2017 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $114.48 Million | -36.47% |
| 2023-12-31 | $180.20 Million | +73.42% |
| 2022-12-31 | $103.91 Million | -22.01% |
| 2021-12-31 | $133.23 Million | -29.68% |
| 2020-12-31 | $189.47 Million | +52.34% |
| 2019-12-31 | $124.37 Million | +70.66% |
| 2018-12-31 | $72.88 Million | +844.26% |
| 2017-12-31 | $7.72 Million | -- |
About Quince Therapeutics, Inc.
Quince Therapeutics, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. The company's lead asset candidature comprises EryDex for the treatment of rare pediatric neurodegenerative disease, including A-T, an inherited autosomal recessive neurodegenerative and immunodeficiency disorder caused by mut… Read more